Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

NCT04849377 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT04849377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04849377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Phase 2
Overall status
Withdrawn
Start date
June 14, 2022
Completion date
June 14, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma (hnscc), human papillomavirus (hpv)